BR112013001432A2 - method to identify a patient most likely to respond and to anticancer therapy - Google Patents

method to identify a patient most likely to respond and to anticancer therapy

Info

Publication number
BR112013001432A2
BR112013001432A2 BR112013001432A BR112013001432A BR112013001432A2 BR 112013001432 A2 BR112013001432 A2 BR 112013001432A2 BR 112013001432 A BR112013001432 A BR 112013001432A BR 112013001432 A BR112013001432 A BR 112013001432A BR 112013001432 A2 BR112013001432 A2 BR 112013001432A2
Authority
BR
Brazil
Prior art keywords
respond
patient
identify
anticancer therapy
anticancer
Prior art date
Application number
BR112013001432A
Other languages
Portuguese (pt)
Inventor
D Plowman Gregory
Andres Herbert
Karl Johann
Wild Norbert
Elliott Rebecca
Lysbet De Haas Sanne
Scherer Stefan
Gloria Meng Yu-Ju
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Priority claimed from PCT/EP2011/062230 external-priority patent/WO2012010550A1/en
Publication of BR112013001432A2 publication Critical patent/BR112013001432A2/en

Links

BR112013001432A 2010-07-19 2011-07-18 method to identify a patient most likely to respond and to anticancer therapy BR112013001432A2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP10170008 2010-07-19
EP10170004 2010-07-19
US41486110P 2010-11-17 2010-11-17
US201161497764P 2011-06-16 2011-06-16
PCT/EP2011/062230 WO2012010550A1 (en) 2010-07-19 2011-07-18 Method to identify a patient with an increased likelihood of responding to an anti-cancer therapy

Publications (1)

Publication Number Publication Date
BR112013001432A2 true BR112013001432A2 (en) 2019-09-24

Family

ID=68057912

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013001432A BR112013001432A2 (en) 2010-07-19 2011-07-18 method to identify a patient most likely to respond and to anticancer therapy

Country Status (1)

Country Link
BR (1) BR112013001432A2 (en)

Similar Documents

Publication Publication Date Title
BR112013001429A2 (en) method of identifying patients most likely to respond to anticancer therapy
CY2018029I1 (en) ANTI-VIRAL THERAPY
CO7020878A2 (en) Combined antibody therapy against human csf-1r and its uses
CO7190236A2 (en) Methods to reduce the risk of a cardiovascular event in a subject with statin therapy
DK2863990T3 (en) MEDICAL MICROELECTRODE
BR112013015089A2 (en) methods and systems to encourage athletic activity
CO6930321A2 (en) Tissue healing
BR112013007499A2 (en) pyridazinones - rearing methods and uses
BR112013013663A2 (en) substituted 1-benzylcycloalkylcarboxylic acids and their use
SMT201500233B (en) METHODS TO DETECT MEDICINE ANTI-CORPS
DK3162386T3 (en) Implantable medical devices
DK3335652T3 (en) Medical fastener
BR112014006419A2 (en) Methods to Treat a Cancer Patient, Kit and Article
DK2569319T3 (en) Heteroaryl-cyclohexyl TETRAAZABENZO [e] azulenes
BR112015002681A2 (en) method to treat a patient and kit
ES2714390T8 (en) Ultrasound therapy applicator
DK2444068T3 (en) Brimonide gel preparation
DK2869858T3 (en) DECELLULAR MUSCLE MATRIX
BR112013008074A2 (en) pharmaceutical combinations
BR112014013694A2 (en) method to treat a disease and kit
SMT201700103B (en) THERAPEUTIC AND DIAGNOSTIC TARGET
DK2450737T3 (en) High-axis collimator unit
BR112014012135A2 (en) medical compression and support socks
DK2590565T3 (en) BLOOD
FR2955473B1 (en) STRUCTURE OF DISPLAY

Legal Events

Date Code Title Description
B08F Application fees: dismissal - article 86 of industrial property law
B08K Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87)

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.